SCHEMBL4069671

SCHEMBL4069671

c1ccc(-c2cc3ncnc(NCCc4cccnc4)c3s2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPR1 P16066 3/20 0.54
FLT1 P17948 6/20 0.53
GBA1 P04062 3/20 0.51
EGFR P00533 4/20 0.47
LMNA P02545 2/20 0.47
MAPK1 P28482 2/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C19 P33261 2/20 0.47
HSD17B10 Q99714 2/20 0.47
CLK4 Q9HAZ1 2/20 0.47
USP2 O75604 1/20 0.47
HIF1A Q16665 1/20 0.47
IKBKB O14920 1/20 0.47
PRKCI P41743 1/20 0.47
PDE5A O76074 2/20 0.47
APP P05067 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24466947 0.90 NPR1 (0.66) NPR1FLT1EGFRLMNAMAPK1
SCHEMBL4067658 0.90 FLT1 (0.61) FLT1EGFRLMNAMAPK1ALDH1A1
SCHEMBL4069349 0.84 FLT1 (0.57) FLT1EGFRLMNAMAPK1ALDH1A1
SCHEMBL4071814 0.82 FLT1 (0.55) FLT1EGFRLMNAMAPK1ALDH1A1
SCHEMBL4072529 0.82 TYK2 (0.60) FLT1EGFRLMNAMAPK1IKBKB
SCHEMBL3936767 0.80 NPR1 (0.61) NPR1FLT1EGFRLMNAMAPK1
SCHEMBL3930448 0.78 FLT1 (0.56) FLT1EGFRLMNAMAPK1ALDH1A1
SCHEMBL4066934 0.78 CA1 (0.54) FLT1EGFRLMNAALDH1A1IKBKB
SCHEMBL5313913 0.77 CLK4 (0.52) NPR1FLT1LMNAMAPK1ALDH1A1
SCHEMBL4015518 0.76 FLT1 (0.54) FLT1EGFRLMNAMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007422-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 NPR1 1200/4885FLT1 3521/4885GBA1 3675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.